Clinical

Ruxolitinib is increasingly being used in patients with graft-vs-host-disease (GVHD); a recent study found a link with transplant-associated thrombotic microangiopathy (TA-TMA) in patients with GVHD treated with the therapy.

For patients with diffuse large B-cell lymphoma (DLBCL), PET/CT scans conducted in the first cycle of salvage therapy can predict for response, according to a study.

A review looks at techniques to monitor minimal residual disease (MRD) in patients with multiple myeloma (MM).

Results of the SAFINONMOTOR open-label study found that safinamide was safe and effective in improving pain of patients with Parkinson disease at 6 months.

The murine study, which assessed the combination of foretinib and an anti–PD-1 antibody, found that the regimen enhanced antitumor activity, offering promise in a cancer that has seen less success with immunotherapies than others.

Investigators identified serial liquid biopsy as an effective tool for identifying mutational changes of RAS genes in patients with metastatic colorectal cancer (mCRC) who have undergone antiangiogenic therapy.

Most studies to date that show efficacy with ruxolitinib in this setting have been in adult patients.

The product, lonapegsomatropin, is a sustained-release formulation and could replace daily injections.

The study, using a BCR/ABL1 assay, found that the novel method is able to detect minimal residual disease (MRD) in a larger range of patients compared with quantitative real‐time polymerase chain reaction, the method currently used to detect MRD.

The approval of zanubrutinib makes it just the second therapy indicated for this rare type of lymphoma.

The findings, if confirmed in subsequent research, could prove to have significant implications, as only a small subset of patients with chronic lymphocytic leukemia (CLL) respond to chimeric antigen receptor (CAR) T-cell therapy.

The European Respiratory Society International Congress 2021 will feature a wide array of topics, such as gender and respiratory health, the impact of climate change, and management and treatment of chronic cough, but there remains a strong focus on the COVID-19 pandemic, its intersection with respiratory care and treatment of infection.

Results of a multicenter study showed 43% of patients with advanced melanoma treated with anti–programmed cell death 1 therapy experienced chronic complications.

A review of treatment options in diffuse large B-cell lymphoma (DLBCL) addresses common subtypes and patient response to standard of care.

Research shows higher levels of interleukin 6 in patients with chronic coronary syndrome were associated with an increased risk of cardiovascular events in patients with chronic kidney disease.

The 5-year update could help solidify the role of sodium glucose co-transporter 2 (SGLT2) inhibitors in treating heart failure, years after the first evidence of their effectiveness emerged.

Researchers said the blood test offers an earlier warning of hepatocellular carcinoma than current methods.

Foundation Medicine and Epic struck a deal to integrate comprehensive genomic profiling within Epic's electronic health records (EHRs), allowing for providers to order and review genomic profiling tests, leading to more streamlined clinical decision making.

The genomic alterations in prostate cancer were detected from tissue biopsies of primary tumors and metastatic sites as well as from liquid biopsies of circulating tumor DNA, the latter of which has emerged as an increasingly popular method for genomic analyses across various types of cancer.

Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.

Pfizer's COVID-19 vaccine has gained full approval from the FDA.

Circulating tumor DNA (ctDNA) is a noninvasive way to identify mutations that may impact treatment decisions, according to a study of patients with metastatic colorectal cancer (mCRC).

The findings come from a pooled analysis of the ELIANA and ENSIGN trials, both of which led to the approval of tisagenlecleucel for these patients.

Over the course of treatment, patients with relapsed/refractory acute myeloid leukemia (AML) may acquire new TP53 mutations, making ongoing monitoring for mutations crucial.

For pediatric patients with T-cell origin lymphoblastic leukemia (T-LBL) with disease progression following second-line treatment, investigators found that the JAK1/2 pathway may be a new actionable target through treatment with ruxolitinib.

Comorbid cardiac dysfunction and intrarenal venous congestion were shown in this new study to have a negative correlation with survival outcomes among individuals with all levels of heart failure.

A review of therapies for atopic dermatitis (AD) found adequate net health benefit for new treatments. However, safety remains a concern for the Janus kinase (JAK) inhibitors.

A study suggests that for patients with chronic kidney disease (CKD), the more components of metabolic syndrome present, the higher that patient’s risk of adverse cardiovascular outcomes.

Few cases have documented how myeloproliferative neoplasms, such as polycythemia vera, progress to pure erythroid leukemia, with just 5 such cases reported between 1952 and 1962.

A new report could eventually help investigators better understand which patients with diffuse large B-cell lymphoma (DLBCL) are most likely to respond to certain therapies.